Faeth Therapeutics, Inc. (FTH) vs Gyre Therapeutics, Inc. (GYRE)

Faeth Therapeutics, Inc. and Gyre Therapeutics, Inc. are both Biotechnology companies. Faeth Therapeutics, Inc. and Gyre Therapeutics, Inc. are of similar size ($777.2M and $750.7M). Faeth Therapeutics, Inc. has the higher net margin (0.00% vs −13.7%) and the higher return on invested capital (0.00% vs −8.51%). Across the 13 metrics below, Faeth Therapeutics, Inc. leads on 7 and Gyre Therapeutics, Inc. on 6.

Valuation

Metric FTH GYRE Biotechnology median
P/E n/m n/m 7.88
P/S n/m 6.35 11.47
P/B 0.91 5.19 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.13 n/m 0.74
EV/Sales n/m 5.71 10.73
Earnings yield (505.89%) (2.72%) (28.84%)
Free cash flow yield (21.43%) (0.96%) (23.03%)

Profitability

Metric FTH GYRE Biotechnology median
Gross margin 0.00% 94.15% 65.16%
Operating margin 0.00% (10.53%) 0.00%
Net margin 0.00% (13.73%) 0.00%
Free cash flow margin 0.00% (6.12%) 0.00%
Return on equity (195.26%) (11.75%) (57.72%)
Return on assets (176.88%) (9.08%) (49.22%)
Return on invested capital 0.00% (8.51%) 0.00%

Growth

Metric FTH GYRE Biotechnology median
Revenue growth (TTM) — 10.72% 5.64%
EPS growth (last fiscal year) 30.33% (60.00%) —
Revenue growth, 5-year CAGR — 40.96% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FTH GYRE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 19.69 4.26 4.73
Net debt to EBITDA 0.96 (3.74) 0.96

Dividend

Metric FTH GYRE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric FTH GYRE Biotechnology median
Market cap 750.66m 777.23m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack